BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 10623696)

  • 1. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
    Braun S; Kentenich C; Janni W; Hepp F; de Waal J; Willgeroth F; Sommer H; Pantel K
    J Clin Oncol; 2000 Jan; 18(1):80-6. PubMed ID: 10623696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
    Janni W; Rack B; Schindlbeck C; Strobl B; Rjosk D; Braun S; Sommer H; Pantel K; Gerber B; Friese K
    Cancer; 2005 Mar; 103(5):884-91. PubMed ID: 15666325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
    Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
    Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy.
    Braun S; Cevatli BS; Assemi C; Janni W; Kentenich CR; Schindlbeck C; Rjosk D; Hepp F
    J Clin Oncol; 2001 Mar; 19(5):1468-75. PubMed ID: 11230493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse.
    Braun S; Schindlbeck C; Hepp F; Janni W; Kentenich C; Riethmüller G; Pantel K
    J Clin Oncol; 2001 Jan; 19(2):368-75. PubMed ID: 11208828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma.
    Janni W; Gastroph S; Hepp F; Kentenich C; Rjosk D; Schindlbeck C; Dimpfl T; Sommer H; Braun S
    Cancer; 2000 May; 88(10):2252-9. PubMed ID: 10820346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
    Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
    Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients.
    Pierga JY; Bonneton C; Vincent-Salomon A; de Cremoux P; Nos C; Blin N; Pouillart P; Thiery JP; Magdelénat H
    Clin Cancer Res; 2004 Feb; 10(4):1392-400. PubMed ID: 14977842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis.
    Thorban S; Rosenberg R; Busch R; Roder RJ
    Br J Cancer; 2000 Jul; 83(1):35-9. PubMed ID: 10883665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    Braun S; Pantel K; Müller P; Janni W; Hepp F; Kentenich CR; Gastroph S; Wischnik A; Dimpfl T; Kindermann G; Riethmüller G; Schlimok G
    N Engl J Med; 2000 Feb; 342(8):525-33. PubMed ID: 10684910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
    Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
    Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
    Thurm H; Ebel S; Kentenich C; Hemsen A; Riethdorf S; Coith C; Wallwiener D; Braun S; Oberhoff C; Jänicke F; Pantel K
    Clin Cancer Res; 2003 Jul; 9(7):2598-604. PubMed ID: 12855636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.
    Drageset V; Nesland JM; Erikstein B; Skovlund E; Sommer H; Anker G; Wist E; Lundgren S; Bergh J; Kvalheim G
    Int J Cancer; 2006 Jun; 118(11):2877-81. PubMed ID: 16381016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].
    Rack B; Schindlbeck C; Strobl B; Sommer H; Friese K; Janni W
    Dtsch Med Wochenschr; 2008 Feb; 133(7):285-9. PubMed ID: 18253918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
    Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
    Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.
    Slade MJ; Singh A; Smith BM; Tripuraneni G; Hall E; Peckitt C; Fox S; Graham H; Lüchtenborg M; Sinnett HD; Cross NC; Coombes RC
    Int J Cancer; 2005 Mar; 114(1):94-100. PubMed ID: 15523696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DTCs in breast cancer: clinical research and practice.
    Janni W; Rack B; Kasprowicz N; Scholz C; Hepp P
    Recent Results Cancer Res; 2012; 195():173-8. PubMed ID: 22527504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.